Nothing Special   »   [go: up one dir, main page]

MX2015010892A - Compuestos antivirales. - Google Patents

Compuestos antivirales.

Info

Publication number
MX2015010892A
MX2015010892A MX2015010892A MX2015010892A MX2015010892A MX 2015010892 A MX2015010892 A MX 2015010892A MX 2015010892 A MX2015010892 A MX 2015010892A MX 2015010892 A MX2015010892 A MX 2015010892A MX 2015010892 A MX2015010892 A MX 2015010892A
Authority
MX
Mexico
Prior art keywords
compounds
antiviral compounds
formula
variables
prevention
Prior art date
Application number
MX2015010892A
Other languages
English (en)
Inventor
Qingjie Ding
Nan Jiang
Robert J Weikert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015010892A publication Critical patent/MX2015010892A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención describe los compuestos de la Fórmula I: (ver Fórmula) en donde las variables en la Fórmula I se definen como se describe en la presente. También se describen composiciones farmacéuticas que contienen tales compuestos y métodos para utilizar los compuestos de la Fórmula I en la prevención o el tratamiento de la infección por VHC.
MX2015010892A 2013-03-05 2014-03-03 Compuestos antivirales. MX2015010892A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772936P 2013-03-05 2013-03-05
PCT/EP2014/054016 WO2014135472A1 (en) 2013-03-05 2014-03-03 Antiviral compounds

Publications (1)

Publication Number Publication Date
MX2015010892A true MX2015010892A (es) 2015-12-03

Family

ID=50190454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010892A MX2015010892A (es) 2013-03-05 2014-03-03 Compuestos antivirales.

Country Status (10)

Country Link
US (1) US20160002180A1 (es)
EP (1) EP2964626A1 (es)
JP (1) JP2016510050A (es)
KR (1) KR20150123917A (es)
CN (1) CN105051026A (es)
BR (1) BR112015021001A2 (es)
CA (1) CA2900826A1 (es)
MX (1) MX2015010892A (es)
RU (1) RU2015136816A (es)
WO (1) WO2014135472A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202010907VA (en) * 2018-05-04 2020-12-30 Inflazome Ltd Novel compounds
CN111518042B (zh) * 2020-05-29 2021-07-30 赣南师范大学 一种1,2,4-三唑类化合物及其制备方法
CN115047117B (zh) * 2022-07-18 2023-06-16 北京云鹏鹏程医药科技有限公司 一种同时测定利奈唑胺中3种遗传毒杂质的检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10123586A1 (de) * 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
WO2004014868A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
JP2006528617A (ja) * 2003-07-24 2006-12-21 ファーマジーン ラボラトリーズ リミテッド ５−ｈｔ２ｂ受容体アンタゴニスト
US8492415B2 (en) * 2007-07-03 2013-07-23 Yale University Azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy (HIV)
EP2800561B1 (en) * 2012-01-06 2020-08-19 Anji Pharma (US) LLC Biguanide compositions and methods of treating metabolic disorders
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
JP6122514B2 (ja) * 2013-03-05 2017-04-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ウイルス化合物

Also Published As

Publication number Publication date
BR112015021001A2 (pt) 2017-07-18
CA2900826A1 (en) 2014-09-12
US20160002180A1 (en) 2016-01-07
JP2016510050A (ja) 2016-04-04
KR20150123917A (ko) 2015-11-04
RU2015136816A (ru) 2017-04-07
CN105051026A (zh) 2015-11-11
EP2964626A1 (en) 2016-01-13
WO2014135472A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
MX2015011193A (es) Compuestos antivirales.
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
PH12016501379A1 (en) Azepane derivatives and methods of treating hepatitis b infections
MY177804A (en) Hcv polymerase inhibitors
NZ733174A (en) Quinazoline derivatives used to treat hiv
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
IN2015DN01156A (es)
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
EA201690979A1 (ru) Производные азепана и способы лечения инфекций гепатита в
MY188114A (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PH12015502588A1 (en) 4`-fluoro-2`-methyl substituted nucleoside derivatives
MX2014015884A (es) Compuestos antivirales.
NZ703064A (en) Inhibitors of hepatitis c virus
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX2015011198A (es) Compuestos antivirales.
IN2014CN00572A (es)
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
PH12016500320A1 (en) Cyclosporin analogues for preventing or treating hepatitis c
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
MX2015009176A (es) Derivados de triazola antivirales.
MX2015010892A (es) Compuestos antivirales.
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c